Search
News Archive
Categories
Regus Advisors Signs Algae Biofuel Agreement – New BioFuel Venture in California
Posted On: April 13, 2012Regus Advisors Inc., a private global Investment Banking firm, announced today that it has completed an agreement to provide its professional advisory services with (AIGI) Algae International Group Inc., for the development of their first $2,000,000 “Algae2BioFuel” Limited Partnership Venture in California.
Sapphire Energy gets $144M in its fuel tank to turn algae into gasoline
Posted On: April 13, 2012Sapphire Energy, a company that creates algae-based fuel, just announced a whopping $144 million in funding.
In recent years several startups have emerged to create fuel out of plant material, all hoping to lure people away from gasoline made from crude oil. Solazyme, Algae.tec, and Sapphire Energy all dominate the space, trying to edge out not only each other but oil companies as well.
All three companies covert algae into a petroleum replacement, one that can work with the traditional cars we already have on the road.
Health Enhancement Products, Inc. Expands Intellectual Property Development Effort With Preeminent Research Scientist and Patent Counsel
Posted On: April 13, 2012Arizona-based algae producer Health Enhancement Products (OTCBB: HEPI) has engaged preeminent research scientist Dr. William Gerwick, Distinguished Professor of Oceanography and Pharmaceutical Sciences at the Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences located in the La Jolla campus of the University of California at San Diego.
Dr. Gerwick’s current research focuses on the discovery of bioactive molecules with potential anticancer, antibacterial, neurotoxic, antiviral, or anti-inflammatory activity from marine organisms, such as algae. The pathways by which these complex molecules are assembled form the basis of Dr. Gerwick’s research, using stable isotope tracer methods and NMR analysis. Many marine algae produce prostaglandin and leukotriene analogs that are strikingly similar to substances produced in the human body, and that have therapeutic value as potential pharmacological agents.
OriginOil looks to build urban algae farm to treat wastewater and generate heat for homes
Posted On: April 3, 2012Algae are getting more attention from the world of science for its possible uses as a source of alternative energy. These simple organisms are very easy to manage and have shown strong resilience to a variety of environments that would be somewhat hostile to other life forms. As such, Algae have become a popular subject for use as a form of organic power. OriginOil, a company that converts algae into fuel, is looking to show off the uses for the organism in a new pilot project that will be launched in Los Angeles, California, at some point this year.
The company is working to create an urban algae farm that will be used to grow algae from wastewater.
Indian ministry test-drives diesel vehicle on algae-derived B100
Posted On: April 3, 2012The Indian Ministry of Science and Technology announced the government’s first test-run of 100 percent algae-derived biodiesel in a Chevrolet Tavera, a diesel multi-utility vehicle made by General Motors for the Indian market. The event took place March 30.
OECD Conference on Marine Biotechnology for Ocean Productivity and Sustainability: May 30-31 2012
Posted On: March 23, 2012This conference, held in late May in Vancouver, Canada, will address opportunities for marine biotechnology to contribute to global challenges such as of food and fuel security, population health, green growth and sustainable industries. The event aims at raising awareness among policy makers of the potential of the marine environment and how this potential could be realized through the use of marine biotechnology, in particular in the areas of generating economic benefit and environmental sustainability.
North Carolina’s Marine Biotechnology Center of Innovation Hires New CEO
Posted On: March 23, 2012Marine research in coastal NC will soon have a fresh flux of energy. The first Chief Executive Officer has been hired for the Marine Biotechnology Center of Innovation. Dr. Deborah Mosca began her new role on March 10.
Launched through funding of a Center of Innovation grant provided by the North Carolina Biotechnology Center, the MBCOI will be a catalyst for commercialization, partnership and entrepreneurial and fiscal investments for marine-based research and innovations. The MBCOI strives to be a sustainable, not-for-profit entity which will integrate marine biotechnology-based research, services, innovations, and entities to identify and meet market needs.
Shrimp shell nanoparticle combats microbes, heals wounds
Posted On: March 23, 2012Nanoparticle-sized Chitosan has shown promise in effectively combating Staphylococcus saprophyticus and E. coli.
Chitosan is a natural, non-toxic and biodegradable, obtained from chitin, the main component of the shells of shrimp, lobster and the beak of the octopus and squid.
It could be used as a protective wound-healing material to avoid opportunistic infection as well as working to facilitate wound healing, the International Journal of Nano and Biomaterials reports.
Mihaela Leonida of Fairleigh Dickinson University, in Teaneck, New Jersey, colleagues reported how they have prepared nanoparticles of chitosan that could potentially preventing infection in wounds as well as enhancing the wound-healing by stimulating skin cell growth.
Marine Drugs Announces New Issue: Mar. Drugs, Volume 10, Issue 3
Posted On: March 23, 2012MDPI recently announced the publication of the following issue:
Mar. Drugs, Volume 10, Issue 3 (March 2012), Pages Pages 521-676
http://www.mdpi.com/1660-3397/10/3/
Table of Contents:
Jing Tong, Hank Trapido-Rosenthal, Jun Wang, Youwei Wang, Qing X. Li and Yuanan Lu
Article: Antiviral Activities and Putative Identification of Compounds in Microbial Extracts from the Hawaiian Coastal Waters
Mar. Drugs 2012, 10(3), 521-538; doi:10.3390/md10030521
http://www.mdpi.com/1660-3397/10/3/521/
Li Sun, Dongli Li, Meihua Tao, Yuchan Chen, Feijun Dan and Weimin Zhang
Article: Scopararanes C–G: New Oxygenated Pimarane Diterpenes from the Marine Sediment-Derived Fungus Eutypella scoparia FS26
Mar. Drugs 2012, 10(3), 539-550; doi:10.3390/md10030539
http://www.mdpi.com/1660-3397/10/3/539/
Zeping Xie, Bing Liu, Hongpeng Wang, Shengxiang Yang, Hongyu Zhang, Yipeng Wang, Naiyun Ji, Song Qin and Hartmut Laatsch
Article: Kiamycin, a Unique Cytotoxic Angucyclinone Derivative from a Marine Streptomyces sp.
Mar. Drugs 2012, 10(3), 551-558; doi:10.3390/md10030551
http://www.mdpi.com/1660-3397/10/3/551/
Yun-Jing Chai, Cheng-Bin Cui, Chang-Wei Li, Chang-Jing Wu, Cong-Kui Tian and Wei Hua
Article: Activation of the Dormant Secondary Metabolite Production by Introducing Gentamicin-Resistance in a Marine-Derived Penicillium purpurogenum G59
Mar. Drugs 2012, 10(3), 559-582; doi:10.3390/md10030559
http://www.mdpi.com/1660-3397/10/3/559/
Danielle F. Mello, Eliza S. de Oliveira, Renato C. Vieira, Erik Simoes, Rafael Trevisan, Alcir Luiz Dafre and Margherita Anna Barracco
Article: Cellular and Transcriptional Responses of Crassostrea gigas Hemocytes Exposed in Vitro to Brevetoxin (PbTx-2)
Mar. Drugs 2012, 10(3), 583-597; doi:10.3390/md10030583
http://www.mdpi.com/1660-3397/10/3/583/
Yan-Bo Zeng, Hui Wang, Wen-Jian Zuo, Bo Zheng, Tao Yang, Hao-Fu Dai and Wen-Li Mei
Article: A Fatty Acid Glycoside from a Marine-Derived Fungus Isolated from Mangrove PlantScyphiphora hydrophyllacea
Mar. Drugs 2012, 10(3), 598-603; doi:10.3390/md10030598
http://www.mdpi.com/1660-3397/10/3/598/
Nicolantonio D’Orazio, Eugenio Gemello, Maria Gammone, Massimo de Girolamo, Cristiana Ficoneri and Graziano Riccioni
Review: Fucoxantin: A Treasure from the Sea
Mar. Drugs 2012, 10(3), 604-616; doi:10.3390/md10030604
http://www.mdpi.com/1660-3397/10/3/604/
Wan-Yu Lin, Yi Lu, Bo-Wei Chen, Chiung-Yao Huang, Jui-Hsin Su, Zhi-Hong Wen, Chang-Feng Dai, Yao-Haur Kuo and Jyh-Horng Sheu
Article: Sarcocrassocolides M–O, Bioactive Cembranoids from the Dongsha Atoll Soft CoralSarcophyton crassocaule
Mar. Drugs 2012, 10(3), 617-626; doi:10.3390/md10030617
http://www.mdpi.com/1660-3397/10/3/617/
Hou-Jin Li, Ying-Lu Xie, Zhong-Liang Xie, Ying Chen, Chi-Keung Lam and Wen-Jian Lan
Article: Chondrosterins A–E, Triquinane-Type Sesquiterpenoids from Soft Coral-Associated FungusChondrostereum sp.
Mar. Drugs 2012, 10(3), 627-638; doi:10.3390/md10030627
http://www.mdpi.com/1660-3397/10/3/627/
Min-Juan Xu, Xiao-Jin Liu, Yi-Lei Zhao, Dong Liu, Zhen-Hao Xu, Xiao-Meng Lang, Ping Ao, Wen-Han Lin, Song-Lin Yang, Zhi-Gang Zhang and Jun Xu
Article: Identification and Characterization of an Anti-Fibrotic Benzopyran Compound Isolated from Mangrove-Derived Streptomyces xiamenensis
Mar. Drugs 2012, 10(3), 639-654; doi:10.3390/md10030639
http://www.mdpi.com/1660-3397/10/3/639/
Yuta Kudo, Takeshi Yasumoto, Keiichi Konoki, Yuko Cho and Mari Yotsu-Yamashita
Article: Isolation and Structural Determination of the First 8-epi-type Tetrodotoxin Analogs from the Newt, Cynops ensicauda popei, and Comparison of Tetrodotoxin Analogs Profiles of This Newt and the Puffer Fish, Fugu poecilonotus
Mar. Drugs 2012, 10(3), 655-667; doi:10.3390/md10030655
http://www.mdpi.com/1660-3397/10/3/655/
Zhuang Han, Ying Xu, Oliver McConnell, Lingli Liu, Yongxin Li, Shuhua Qi, Xiangzhong Huang and Peiyuan Qian
Article: Two Antimycin A Analogues from Marine-Derived Actinomycete Streptomyces lusitanus
Mar. Drugs 2012, 10(3), 668-676; doi:10.3390/md10030668
http://www.mdpi.com/1660-3397/10/3/668/
Scots and Aussie scientists team up to research marine microbes
Posted On: March 12, 2012A leading Scottish marine biotechnology firm has joined forces with the Australian Institute of Marine Science (AIMS) in a bid to discover innovative and high-value products from micro-organisms.
Scientists from Aquapharm Biotechnology are to be given exclusive commercial access to a selection of Australian marine microbes in the AIMS Bioresources Library.
Aquapharm believes the deal will lead to the discovery of useful new active ingredients for use in pharmaceutical, nutritional and personal care products.
Jon Williams, VP Commercial at Aquapharm, explained: “AIMS is amongst the world’s top specialist research institutions, and it has cultivated a sizeable collection of marine micro-organisms from Australia’s unique marine territory. This territory spans an immense 16 million square kilometres, leading to high biodiversity and the potential for novel microbes and their products.
“Aquapharm has signed an agreement with AIMS that grants us exclusive commercial access to a select range of these organisms for testing and development, with the option to conclude an exclusive licence agreement for commercialization if they are found to be suitable.
Host
 |
Partners
  |
Sponsors
 |
 |
Share Aquapreneur
